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Reply:
We are disappointed that the Cochrane group 
remains unconvinced that sustained virologic 
response (SVR) is a validated surrogate outcome 
and that direct-acting antiviral agents (DAAs) have 
been demonstrated to improve clinical as well as 
patient-reported outcomes in patients with chronic 
hepatitis C. Since our commentary in 2017, there 
have been many more studies supporting the bene-
fits of SVR and DAA therapies, including a decline 
in patients added to the waiting list for liver trans-
plantation for hepatitis C. We recognize that ran-
domized controlled trial is the gold standard for 
showing the benefits of treatments, but given the 
robust evidence from clinical trials and observational 
studies all over the world, we do not believe that it is 
ethical to contemplate withholding clinically proven 
beneficial therapy. We stand by our associations’ 
recommendations that all patients with chronic hep-
atitis C should be treated.
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Letter to Editor: Using Proper Methods to Identify Patients With 
Cirrhosis in Administrative Databases Is Crucial to Correctly 
Predict Outcomes
TO THE EDITOR:
We would like to congratulate Mumtaz et al.(1) for 
their important study attempting to develop and vali-
date a risk score to predict 30-day hospital readmission 
in patients with decompensated cirrhosis using the US 
nationwide readmission database (NRD). Identifying 
patients with cirrhosis at high risk for readmission is 
critical for developing processes to effectively address 
this problem. However, flaws in patient identification 
challenge the utility of the risk score outlined in this 
study. Specifically, the authors failed to discuss their 
observed high readmission rates in the context of pub-
lished data from the large multistate study by Tapper 
et al.(2) The NRD consists of patient data from multi-
ple state inpatient databases (SID). Tapper et al. used 
SID data from five large geographically diverse states 
to describe 12.9% to 24.2% 30-day readmission rates 
in patients with 1-3 cirrhosis decompensation features, 
respectively. In contrast, Mumtaz et al. report a base-
line 30-day readmission rate of 27%—an unexpected 
significant difference in readmission rates, given that 
the NRD is based on SID. This variation could be 
due to the case definition of decompensated cirrhosis. 
Specifically, the authors defined decompensated cirrho-
sis as the presence of cirrhosis plus any of the follow-
ing: ascites, hepatic encephalopathy, variceal bleeding, 
or spontaneous bacterial peritonitis. However, in 
reviewing their coding, the International Classification 
of Disease Ninth Edition (ICD-9) clinical modifica-
tion codes 348.30, 348.39, and 780.97 were included, 
which describe general encephalopathy or altered men-
tal status. The authors cite two studies to support the 
use of these codes. However, no study has in fact vali-
dated these codes in patients with cirrhosis. Similarly, 
the authors used nonvalidated codes for coagulopathy. 
There are important studies describing the validity of 
ICD-9 codes to identify patients with cirrhosis.(3,4) 
The use of well-validated codes to identify patients 
